Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Scientists demonstrate new approach for quickly assembling drug-like compounds

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.

11 Feb 2013

Innovative drug discovery in Europe supported by Bayer

Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named European Lead Factory, which has been launched to enhance early drug discovery addressing the need for innovative drugs. The new five-year project will create an exceptional small molecule library collection allowing drug discovery on innovative and promising targets from pharma companies and academia.

7 Feb 2013

MiR-182 deeply involved in memory formation within the amygdala brain structure

It takes a lot to make a memory. New proteins have to be synthesized, neuron structures altered. While some of these memory-building mechanisms are known, many are not. Some recent studies have indicated that a unique group of molecules called microRNAs, known to control production of proteins in cells, may play a far more important role in memory formation than previously thought.

30 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Glenmark third quarter consolidated revenue increases 33.96% to Rs. 13812.59M

Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its results for the third quarter ended December 31, 2012.

30 Jan 2013

Endo Pharmaceuticals, GVK BIO enter research collaboration agreement

GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development CRO announced today that it has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein.

28 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

Targeting key HIV protein could stop HIV infection from progressing to AIDS

Researchers at the University of Pittsburgh School of Medicine may have found an "Achilles heel" in a key HIV protein. In findings published online today in Chemistry and Biology, they showed that targeting this vulnerable spot could stop the virus from replicating, potentially thwarting HIV infection from progressing to full-blown AIDS.

25 Jan 2013

Neuromuscular blockade (NMB) reversal

General anesthesia is made up of three components: hypnotic medicines, to induce sleep; analgesics, or medicines to inhibit pain; and NMB agents that induce muscle relaxation. Anesthesiology professionals use NMB to relax a patient’s muscles and prevent involuntary movement that could impact surgery.

24 Jan 2013

Institute of Bioengineering and Nanotechnology, IBM reveal new antimicrobial hydrogel

Researchers from IBM and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact.

24 Jan 2013

Salk Institute to establish Helmsley Center for Genomic Medicine

The Salk Institute for Biological Studies has received a $42 million gift-the largest in the Institute's history-to establish the Helmsley Center for Genomic Medicine (HCGM), a research center dedicated to decoding the common genetic factors underlying many complex chronic human diseases.

23 Jan 2013

Cancer Targets & Therapeutics Conference to take place from Feb. 25-26 in Las Vegas

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems.

19 Jan 2013

New compounds can target RNase H enzyme in HIV

Scientists who study HIV are facing a troubling consequence of their own success. They created drugs that can now give infected patients almost normal life expectancy. However, those same drugs will eventually cause the constantly mutating virus to evolve into a form that eludes current treatments.

18 Jan 2013

Researchers identify potential sources of medicines derived from plants against diabetes

A group of researchers from the university's School of Science, led by Dr Solomon Habtemariam, believe they have identified potential sources of medicines derived from plants which may have fewer adverse side-effects for diabetes sufferers.

17 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Today, AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer's disease and schizophrenia.

16 Jan 2013

Thermo Fisher's expandable portfolio of lab automation solutions to be showcased at SLAS 2013

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced a new range of laboratory automation and screening solutions during the Second Annual Society for Laboratory Automation and Screening (SLAS) conference and exhibition.

From Thermo Fisher Scientific Inc. 16 Jan 2013

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

11 Jan 2013

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

3 Jan 2013

Kareus announces start of KU-046 Phase I study in Alzheimer's

Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

3 Jan 2013

Drug Discovery News and Research

Further Reading

Scientists demonstrate new approach for quickly assembling drug-like compounds

Innovative drug discovery in Europe supported by Bayer

MiR-182 deeply involved in memory formation within the amygdala brain structure

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Glenmark third quarter consolidated revenue increases 33.96% to Rs. 13812.59M

Endo Pharmaceuticals, GVK BIO enter research collaboration agreement

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Targeting key HIV protein could stop HIV infection from progressing to AIDS

Neuromuscular blockade (NMB) reversal

Institute of Bioengineering and Nanotechnology, IBM reveal new antimicrobial hydrogel

Salk Institute to establish Helmsley Center for Genomic Medicine

Cancer Targets & Therapeutics Conference to take place from Feb. 25-26 in Las Vegas

New compounds can target RNase H enzyme in HIV

Researchers identify potential sources of medicines derived from plants against diabetes

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Vanderbilt University, AstraZeneca partner to identify candidate drugs for major brain diseases

Thermo Fisher's expandable portfolio of lab automation solutions to be showcased at SLAS 2013

UCSF teams to study new ways to reduce childhood mortality and disease in developing nations

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Kareus announces start of KU-046 Phase I study in Alzheimer's

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News